<DOC>
	<DOCNO>NCT00002761</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : Phase I/II trial study effectiveness combination chemotherapy follow peripheral stem cell transplantation treat patient chronic myelogenous leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Followed Peripheral Stem Cell Transplantation Treating Patients With Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether intensive idarubicin cytarabine lead adequate harvest Philadelphia chromosome-negative peripheral blood stem cell ( PBSC ) patient chronic myelogenous leukemia chronic phase . II . Determine toxicity intensive regimen patient . III . Determine graft-versus-leukemia effect induce patient cyclosporine interferon gamma post-PBSC transplantation . IV . Determine transformation-free overall survival patient treat high-dose conditioning regimen comprise busulfan cyclophosphamide follow PBSC transplantation plus immunotherapy . OUTLINE : Patients receive idarubicin IV cytarabine IV 2 hour day 1-3 . When blood count recover , Philadelphia chromosome negative peripheral blood stem cell ( PBSC ) harvest . Filgrastim ( G-CSF ) administer subcutaneously ( SC ) begin 24 hour completion cytarabine infusion continue blood count recover 3 consecutive day harvest PBSC . Patients 5 % blast marrow peripheral blast , interferon resistance , interferon intolerance poor prognosis , clonal evolution proceed condition follow PBSC transplantation . Patients receive condition comprise oral busulfan every 6 hr day -8 -5 cyclophosphamide IV 2 hour day -4 -3 . PBSC reinfused day 0 . Patients receive graft versus leukemia induction comprise cyclosporine IV 4 hour every 12 hour day 0-28 interferon gamma SC begin day 7 continue every day day 28 . Patients follow every 3 month 1 year annually 5 year . PROJECTED ACCRUAL : A total 15-43 patient accrue study within 4-8 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis chronic myelogenous leukemia first chronic phase Philadelphia chromosomepositive Myelofibrosis le 3+ bone marrow biopsy Ineligible allogeneic transplantation No suitable allogeneic sibling donor OR Under 55 year old refuse unrelated donor transplantation unrelated donor available PATIENT CHARACTERISTICS : Age : 18 physiologic 60 Performance status : ECOG 01 Hematopoietic : See Disease Characteristics WBC least 3,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin le 2 time normal ( unless elevation due Gilbert 's disease ) SGOT le 1.5 time normal Renal : Creatinine le 1.5 time normal Cardiovascular : Left ventricular ejection fraction least 50 % Pulmonary : DLCO least 60 % predict Other : HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior interferon alfa Chemotherapy : No concurrent conventional chemotherapy Endocrine therapy : No concurrent steroid chemotherapy Radiotherapy : Not specify Surgery : Not specify Other : No concurrent barbiturates acetaminophen chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic myelogenous leukemia , BCR-ABL1 positive</keyword>
</DOC>